Alios BioPharma Raises $32 Million
Alios BioPharma Inc., a South San Francisco-based drug startup, has closed its Series A round with a total of $32 million. This includes a first close from last December, from firms like Novo AS, Novartis BioVentures and Roche Finance Ltd. The second close came from SR One Ltd., the corporate venture arm of GlaxoSmithKline. The company says that it plans to “treat diseases in virology by activating pathways in the innate immune system.”
12 June 2009•2 mins read
